CLINICAL TRIALS PROFILE FOR APREPITANT

505(b)(2) Clinical Trials for aprepitant

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Indication	NCT00090155 ↗	2 Doses of an Approved Drug Being Studied for a New Indication for the Prevention of Postoperative Nausea and Vomiting (0869-090)(COMPLETED)	Completed	Merck Sharp & Dohme Corp.	Phase 3	2003-09-26	The purpose of this study is to assess the safety and efficacy of 2 doses of an approved drug for a new indication in the prevention of postoperative nausea and vomiting in patients receiving general anesthesia for open abdominal surgery requiring overnight hospital stay.
New Indication	NCT00090246 ↗	2 Doses of an Approved Drug Being Studied for a New Indication for the Prevention of Postoperative Nausea and Vomiting (0869-091)	Completed	Merck Sharp & Dohme Corp.	Phase 3	2004-05-13	The purpose of this study is to assess the safety and efficacy of 2 doses of an approved drug for a new indication in the prevention of postoperative nausea and vomiting in patients receiving general anesthesia for open abdominal surgery requiring overnight hospital stay.
New Combination	NCT01012336 ↗	Safety and Efficacy of Aprepitant, Ramosetron, and Dexamethasone for Chemotherapy-Induced Nausea and Vomiting in Patients With Ovarian Cancer Treated With Taxane/Carboplatin	Completed	Merck Sharp & Dohme Corp.	Phase 2	2010-05-01	The current recommended guideline for patients receiving moderately emetogenic chemotherapy (MEC) is the combination of a 5-HT3 receptor antagonist and corticosteroid. Incidence of chemotherapy induced nausea and vomiting (CINV) is approximately 50% in patients receiving MEC. An incidence rate of 25-38% for delayed emesis and 55-60% for delayed nausea has been observed. Hence, there is clearly a need for more effective prevention of CINV in patients receiving MEC, especially in women with ovarian carcinoma who are particularly susceptible to these symptoms. Therefore the investigators designed a study with the objective to evaluate if new combination (Aprepitant/Ramosetron/Dexamethasone) may improve actual CINV control in ovarian carcinoma patients treated with taxane/carboplatin.
New Combination	NCT01012336 ↗	Safety and Efficacy of Aprepitant, Ramosetron, and Dexamethasone for Chemotherapy-Induced Nausea and Vomiting in Patients With Ovarian Cancer Treated With Taxane/Carboplatin	Completed	Samsung Medical Center	Phase 2	2010-05-01	The current recommended guideline for patients receiving moderately emetogenic chemotherapy (MEC) is the combination of a 5-HT3 receptor antagonist and corticosteroid. Incidence of chemotherapy induced nausea and vomiting (CINV) is approximately 50% in patients receiving MEC. An incidence rate of 25-38% for delayed emesis and 55-60% for delayed nausea has been observed. Hence, there is clearly a need for more effective prevention of CINV in patients receiving MEC, especially in women with ovarian carcinoma who are particularly susceptible to these symptoms. Therefore the investigators designed a study with the objective to evaluate if new combination (Aprepitant/Ramosetron/Dexamethasone) may improve actual CINV control in ovarian carcinoma patients treated with taxane/carboplatin.

All Clinical Trials for aprepitant

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00034983 ↗	Treatment of Patients With Major Depressive Disorder With MK0869 (0869-066)(COMPLETED)	Completed	Merck Sharp & Dohme Corp.	Phase 3	2001-10-29	A clinical study to determine the efficacy and safety of an investigational medication (MK0869) in the treatment of depression
NCT00035048 ↗	Treatment of Patients With Major Depressive Disorder With MK0869 (0869-068)(COMPLETED)	Completed	Merck Sharp & Dohme Corp.	Phase 3	2001-11-21	A clinical study to determine the efficacy and safety of an investigational medication (MK0869) in the treatment of depression.
NCT00035282 ↗	Treatment of Patients With Major Depressive Disorder With MK0869 (0869-060)(COMPLETED)	Completed	Merck Sharp & Dohme Corp.	Phase 3	2001-09-01	A clinical study to determine the efficacy and safety of an investigational medication (MK0869) in the treatment of depression.
NCT00048594 ↗	Long Term Treatment of Patients With Major Depressive Disorder With MK0869 (0869-065)(COMPLETED)	Completed	Merck Sharp & Dohme Corp.	Phase 3	2002-01-03	A clinical study to determine the efficacy and safety of an investigational medication (MK0869) in the treatment of depression.
NCT00048607 ↗	Treatment of Patients With Major Depressive Disorder With MK0869 (0869-062)(COMPLETED)	Completed	Merck Sharp & Dohme Corp.	Phase 3	2002-07-30	A clinical study to determine the efficacy and safety of MK0869 in the treatment of depression

Clinical Trial Conditions for aprepitant

Condition Name

Condition Name for aprepitant
Intervention	Trials
Vomiting	30
Nausea	28
Chemotherapy-induced Nausea and Vomiting	24
Postoperative Nausea and Vomiting	22

Condition MeSH

Condition MeSH for aprepitant
Intervention	Trials
Vomiting	107
Nausea	89
Postoperative Nausea and Vomiting	35
Breast Neoplasms	8

Clinical Trial Locations for aprepitant

Trials by Country

Trials by Country for aprepitant
Location	Trials
United States	134
Italy	19
China	17
Canada	7
Korea, Republic of	7

Trials by US State

Trials by US State for aprepitant
Location	Trials
Pennsylvania	13
New York	11
California	9
North Carolina	9
Texas	8

Clinical Trial Progress for aprepitant

Clinical Trial Phase

Clinical Trial Phase for aprepitant
Clinical Trial Phase	Trials
PHASE4	2
PHASE3	4
PHASE2	3

Clinical Trial Status

Clinical Trial Status for aprepitant
Clinical Trial Phase	Trials
Completed	111
Unknown status	26
Recruiting	14

Clinical Trial Sponsors for aprepitant

Sponsor Name

Sponsor Name for aprepitant
Sponsor	Trials
Merck Sharp & Dohme Corp.	52
National Cancer Institute (NCI)	11
National Institute on Drug Abuse (NIDA)	6

Sponsor Type

Sponsor Type for aprepitant
Sponsor	Trials
Other	193
Industry	74
NIH	21

Aprepitant Clinical Trials Update, Market Analysis, and Future Revenue Projection (Neurokinin-1 Antagonist for CINV)

Last updated: May 20, 2026

Aprepitant (EMEND; neurokinin-1 [NK1] receptor antagonist) remains a mature, high-barrier antiemetic in chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea and vomiting (PONV). The commercial picture is driven by (1) guideline inclusion for highly emetogenic chemotherapy regimens, (2) deep formulary penetration in oncology, and (3) competition from generic aprepitant and supportive-care alternatives. Public clinical-development activity is limited versus peak years; pipeline focus now centers on new combinations, new schedules, and life-cycle reformulations rather than a wholesale new mechanism.

Market outlook summary (directional, evidence-based):

• Base case: flat-to-low single-digit value growth through mid-decade as oncology volumes and guideline-driven prescribing persist, offset by pricing pressure and generics.
• Upside case: modest growth if newer regimens expand adoption (notably guideline concordant multi-day CINV prophylaxis in HEC), plus share stabilization where payers favor NK1-based prophylaxis.
• Downside case: continued erosion from aggressive generic pricing and substitution to lower-cost antiemetic pathways (5-HT3, dexamethasone, olanzapine in some protocols), with net price declines outweighing volume.

Because this request requires a clinical trials update and market projection with quantified forecasts, no complete, accurate response can be produced without drug- and jurisdiction-specific data sources (active trial registries, current FDA label status, and audited market sizing/consensus forecasts).